These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10341850)

  • 1. Cardiovascular disease and risk factors in adults with hypopituitarism.
    Beshyah SA; Johnston DG
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):1-15. PubMed ID: 10341850
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term growth hormone replacement therapy in hypopituitary adults.
    Verhelst J; Abs R
    Drugs; 2002; 62(16):2399-412. PubMed ID: 12396230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone and cardiovascular risk markers.
    Klibanski A
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S109-15. PubMed ID: 12914737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Premature mortality and hypopituitarism.
    Kohno H; Kuromaru R; Ueyama N; Miyako K
    Lancet; 2001 Jun; 357(9272):1973-4. PubMed ID: 11729839
    [No Abstract]   [Full Text] [Related]  

  • 5. Premature mortality due to cardiovascular disease in hypopituitarism.
    Rosén T; Bengtsson BA
    Lancet; 1990 Aug; 336(8710):285-8. PubMed ID: 1973979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of hormonal deficit and cardiovascular risk factors on life expectancy in hypopituitarism].
    Ricart W; Fernández-Real JM
    Med Clin (Barc); 2003 May; 120(16):630-7. PubMed ID: 12732130
    [No Abstract]   [Full Text] [Related]  

  • 7. High prevalence of abnormal circadian blood pressure regulation and impaired glucose tolerance in adults with hypopituitarism.
    Krzyzanowska K; Schnack C; Mittermayer F; Kopp HP; Hofer M; Kann T; Schernthaner G
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):430-4. PubMed ID: 16151976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered lipid pattern explains increased cardiovascular mortality in hypopituitary patients with growth hormone deficiency.
    Rosén T; Wilhelmsen L; Bengtsson BA
    Clin Endocrinol (Oxf); 1998 Apr; 48(4):525-6. PubMed ID: 9640422
    [No Abstract]   [Full Text] [Related]  

  • 9. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone deficiency in adults: a new indication for recombinant human growth hormone.
    Bengtsson BA
    J Intern Med; 1996 Apr; 239(4):283-6. PubMed ID: 8774381
    [No Abstract]   [Full Text] [Related]  

  • 11. Growth hormone deficiency in adults: to treat or not to treat.
    Hoffman DM; Ho KK
    Aust N Z J Med; 1999 Jun; 29(3):342-9. PubMed ID: 10868497
    [No Abstract]   [Full Text] [Related]  

  • 12. GH-replacement therapy in adults.
    Christiansen JS; Jørgensen JO; Pedersen SA; Müller J; Jørgensen J; Møller J; Heickendorf L; Skakkebaek NE
    Horm Res; 1991; 36 Suppl 1():66-72. PubMed ID: 1806489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eternal vigilance--mortality in children with growth hormone deficiency.
    Hintz RL
    J Clin Endocrinol Metab; 1996 May; 81(5):1691-2. PubMed ID: 8626816
    [No Abstract]   [Full Text] [Related]  

  • 14. Growth hormone therapy for adults: not ready for prime time?
    Isley WL
    Ann Intern Med; 2002 Aug; 137(3):190-6. PubMed ID: 12160367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone replacement therapy for growth hormone-deficient adults.
    Powrie J; Weissberger A; Sönksen P
    Drugs; 1995 May; 49(5):656-63. PubMed ID: 7601008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in skeletal muscle after discontinuation of growth hormone treatment in young adults with hypopituitarism.
    Rutherford OM; Jones DA; Round JM; Preece MA
    Acta Paediatr Scand Suppl; 1989; 356():61-3; discussion 64, 73-4. PubMed ID: 2816359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic changes and vascular risk factors in hypopituitarism.
    Johnston DG; Beshyah SA; Markussis V; Shahi M; Sharp PS; Foale RA; Skinner EM
    Horm Res; 1992; 38 Suppl 1():68-72. PubMed ID: 1295816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of adult growth hormone deficiency. Prevalence, incidence, mortality and morbidity.
    Erfurth EM
    Front Horm Res; 2005; 33():21-32. PubMed ID: 16166753
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular outcomes and conventional risk factors in non-diabetic adult patients with GH deficiency: A long-term retrospective cohort study.
    de Gregorio C; Andò G; Cannavò S; Cotta OR; Trio O; Cusmà Piccione M; Trimarchi F; Curtò L
    Eur J Intern Med; 2015 Dec; 26(10):813-8. PubMed ID: 26548714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density.
    Wüster C; Abs R; Bengtsson BA; Bennmarker H; Feldt-Rasmussen U; Hernberg-Ståhl E; Monson JP; Westberg B; Wilton P;
    J Bone Miner Res; 2001 Feb; 16(2):398-405. PubMed ID: 11204440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.